Close Menu

AmberGen

Universidad del Pais Vasco of Leioa-Vizcaya, Spain, has been awarded US Patent No. 8,486,637, "Methods and reagents for the detection of Salmonella spp."

MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."
Ilse Vlassenbroeck and Katja Bierau are named as inventors.

Panasonic of Osaka, Japan, has received US Patent Nos.

AmberGen is developing a microbead-based, multiplexed, in vitro pediatric allergy test. The diagnostic is designed to enable the detection of multiple allergen-specific IgE antibodies in blood, according to a company executive.

Microarray-Related NIH Grants, Jan. 1 – May 10, 2012

NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

Winners of NCI's Bridge awards, which give up to $3 million to cross the biomedical business 'valley of death', include 20/20 GeneSystems, Ambergen, and Advanced Cell Diagnostics.

Paired Ends: Nov 10, 2009

Premium

Christopher Sears

Sequencing-Related US Patents Granted May 20 – June 23

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.